Robert A. Mook

Discovery of 5-[[4-[(2,3-Dimethyl-2<i>H</i>-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methyl-benzenesulfonamide (Pazopanib), a Novel and Potent Vascular Endothelial Growth Factor Receptor Inhibitor

Philip A. Harris, Amogh Boloor, Mui Cheung et al. · Journal of Medicinal Chemistry · 2008 · 345 citations · Full text

Medicine, Medicinal Chemistry, Pharmacology +15

<i>N</i>-(2-Benzoylphenyl)-<scp>l</scp>-tyrosine PPARγ Agonists. 1. Discovery of a Novel Series of Potent Antihyperglycemic and Antihyperlipidemic Agents

Brad R. Henke, Steven G. Blanchard, Marcus F. Brackeen et al. · Journal of Medicinal Chemistry · 1998 · 301 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +10

A serum-resistant cytofectin for cellular delivery of antisense oligodeoxynucleotides and plasmid DNA.

John G. Lewis, Kun Lin, A Kothavale et al. · Proceedings of the National Academy of Sciences · 1996 · 260 citations

Pharmacy, Biotechnology, Pharmaceutics +17

Discovery of Dabrafenib: A Selective Inhibitor of Raf Kinases with Antitumor Activity against B-Raf-Driven Tumors

Tara Rheault, John Stellwagen, George M. Adjabeng et al. · ACS Medicinal Chemistry Letters · 2013 · 258 citations · Full text

Medicine, Oncology, Pharmacology +17

Optimization and SAR for dual ErbB-1/ErbB-2 tyrosine kinase inhibition in the 6-furanylquinazoline series

Kimberly G. Petrov, Yuemei Zhang, Malcolm Carter et al. · Bioorganic & Medicinal Chemistry Letters · 2006 · 164 citations · Full text

Pharmacy, Medicinal Chemistry, Pharmacology +14